Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Total Debt
Short-term and long-term borrowings combined.
Apyx Medical CorporationNASDAQ: APYX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt broadly unchanged from a year ago
Total debt stood at $39.46M at the end of Q1 FY2026, up 1.4% from a year earlier and up 0.3% from the prior quarter. Over 3 fiscal years it compounded at +267.0% a year.
Context
- Total debt amounted to 62.6% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +1.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 39.34M USD
- Year-over-year change
- +1.5%
- 4-year CAGR
- +237.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.34M | +1.5% |
| FY2024 | 2024-12-31 | 38.76M | +0.7% |
| FY2023 | 2023-12-31 | 38.5M | +4736.8% |
| FY2022 | 2022-12-31 | 796K | +161.0% |
| FY2021 | 2021-12-31 | 305K | — |
Total Debt vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's Mar 2026 total debt of $39.46M is the highest of the 8 companies compared; the peer median is $18.28M.
- Its year-over-year change of +1.4% is the 4th highest of 8, against a peer median of -3.5%.
- Total debt amounts to 62.6% of total assets for APYX, versus a peer median of 26.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $39.46M | +1.4% | +267.0% | 62.6% | |
| Mar 2026 | $26.8M | -24.0% | +134.6% | 78.6% | |
| Mar 2026 | $23.71M | +303.5% | +44.2% | 38.0% | |
| Mar 2026 | $20.17M | +3.0% | +1.3% | 26.9% | |
| Mar 2026 | $18.28M | -3.5% | +170.3% | 43.1% | |
| Mar 2026 | $15.44M | -55.0% | +18.9% | 19.8% | |
| Mar 2026 | $2.51M | +341.0% | -6.2% | 2.7% | |
| Mar 2026 | $1.98M | -95.5% | +268.8% | 3.8% | |
| Peer median (excluding APYX) | $18.28M | -3.5% | +44.2% | 26.9% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.87M | 10.19M | 43.65M | 31.74M | 31.74M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 21.16M | 18.25M | 14.02M | 15.48M | 16.78M |
| Inventory | 6.78M | 11.8M | 9.92M | 7.56M | 8.6M |
| Other Current Assets | 0 | 2.74M | 2.76M | 1.66M | 1.35M |
| Total Current Assets | 60.74M | 42.97M | 70.36M | 56.44M | 58.47M |
| Property, Plant & Equipment (Net) | 6.87M | 7.59M | 7.15M | 6.74M | 6.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.11M | 1.22M | 1.73M | 1.66M | 1.75M |
| Total Non-current Assets | 7.98M | 8.8M | 8.88M | 8.4M | 8.37M |
| Total Assets | 68.72M | 51.78M | 79.24M | 64.84M | 66.84M |
| Account Payables | 2.63M | 2.67M | 2.71M | 2.62M | 3.06M |
| Short-term Debt | 0 | 0 | 0 | 355K | 428K |
| Tax Payables | 2.29M | 2.08M | 0 | 0 | 0 |
| Deferred Revenue | 533K | 853K | 488K | 693K | 0 |
| Other Current Liabilities | 2.12M | 0 | 1.55M | 5.08M | 8.21M |
| Total Current Liabilities | 13.21M | 11.85M | 12.74M | 10.72M | 11.7M |
| Long-term Debt | 0 | 0 | 33.19M | 33.89M | 34.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.32M | 1.41M | 1.25M | 1.12M | 1.05M |
| Other Non-current Liabilities | 166K | 181K | 198K | 259K | 347K |
| Total Non-current Liabilities | 1.51M | 2.13M | 39.58M | 39.79M | 40.31M |
| Total Liabilities | 14.71M | 13.98M | 52.32M | 50.51M | 52.01M |
| Common Stock | 34K | 35K | 35K | 38K | 42K |
| Retained Earnings | (12.55M) | (35.74M) | (54.45M) | (77.91M) | (89.12M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 305K | 211K | 221K | 125K | 291K |
| Total Equity | 54.01M | 37.79M | 26.92M | 14.34M | 14.83M |
| Total Debt | 305K | 796K | 38.5M | 38.76M | 39.34M |
| Net Debt | (30.57M) | (9.4M) | (5.15M) | 7.02M | 7.6M |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.